Vascular Targeting Agents: Emerging Competitors

Table of Contents

• Table of Contents2
  • BSG General Working Model & Methodology3
• Introduction5
  • More Vascular Targeting Drugs in Clinical Trial8
  • Table 1 Summary of VTA agents under development9
  • The Vanguard VTA in New Clinical Programs10
  • Combination of VTAs and antiangiogenic agents18
  • The Non-Combretastatins Agents that Destabilize Microtubules21
  • Antimicrotubule Agents with Vascular Targeting Potential27
  • Monoclonal Antibodies as Delivery Vehicles30
  • Targeting Endothelial Cell-Specific Adhesion37
  • Encapsulation in cationic liposomes40
• Disclaimer42
  • Liability42
  • Completeness42
• Appendix43
  • Table 2. CA4P Near Term Progress43
  • Table 3. Oxi 4503 Near Term Progress47
  • Table 4. AVE8062A Near Term Progress48
  • Table 5. ZD6126 Near Term Progress49
  • Table 6. DMXAA Near Term Progress52
  • Table 7. ABT-751 Near Term Progress55
  • Table 8. MN-029 Near Term Progress56
  • Table 9. MX116407 Near Term Progress56
  • Table 10. NPI-2358 Near Term Progress57
  • Table 11. TZT-1027 Near Term Progress58
  • Table 12. ILX-651 Near Term Progress59
  • Table 13. Peregrines VTA and APT platforms Near Term Progress60
  • Table 14. VEGF121/rGelonin Near Term Progress63
  • Table 15. MLN2704 Near Term Progress64
  • Table 16. Adherexs cadherin platform Near Term Progress66
  • Table 17. E4G10 Near Term Progress67
  • Table 18. EndoTAG-1 Near Term Progress68